Drugs Made In America Acquisition Corp.
For the period ended Mar 6, 2026. Filed Mar 6, 2026.
View on SEC.govAbout this filing
A notice of a major event between regular reports, such as results, a deal or a change of executives. It is often the first formal record of the news.
Mar 6, 2026 · Filed Mar 6, 2026
Use the contents to explore the available documents and sections.
Contents
Not Applicable
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
|---|
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
|---|
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
|---|
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c)) |
|---|
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading Symbol(s) | Name of each exchange on which registered |
|---|---|---|
| Units, each consisting of one ordinary share, $0.0001 par value, and one right to receive one-eighth of one ordinary share | DMAAU | The Nasdaq Stock Market LLC |
| Ordinary shares, par value $0.0001 per share | DMAA | The Nasdaq Stock Market LLC |
| Rights, each entitling the holder to receive one-tenth of one Ordinary Share | DMAAR | The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐
Item 8.01. Other Events.
As previously reported in the Current Report on Form 8-K filed with the Securities and Exchange Commission on March 6, 2026, Drugs Made In America Acquisition Corp. (the “Company”) announced that, between the completion of the initial public offering for Drugs Made In America Acquisition II Corp., an affiliate of the Company (the “Affiliate”) on September 26, 2025 and December 31, 2025, the sponsor to the Affiliate made certain improper withdrawals (the “Irregularities”) from the Affiliate’s working capital account.
As a result of the events reported above, the board of directors of the Company immediately took action to confirm that the Irregularities did not extend to the Company’s trust account (the “Trust Account”), and as of today, March 6, 2026, the Company is confirming that approximately $241,292,436 is in the Trust Account.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.